The estimated Net Worth of Loren L Mc Farland is at least 1.12 百万$ dollars as of 11 January 2022. Mr. Farland owns over 2,083 units of Inogen Inc stock worth over 256,528$ and over the last 11 years he sold INGN stock worth over 623,680$. In addition, he makes 235,022$ as Independent Director at Inogen Inc.
Loren has made over 8 trades of the Inogen Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 2,083 units of INGN stock worth 17,435$ on 11 January 2022.
The largest trade he's ever made was exercising 8,333 units of Inogen Inc stock on 23 March 2021 worth over 138,494$. On average, Loren trades about 1,333 units every 170 days since 2014. As of 11 January 2022 he still owns at least 22,191 units of Inogen Inc stock.
You can see the complete history of Mr. Farland stock trades at the bottom of the page.
Loren L. McFarland is an Independent Director of Inogen, Inc. He has been President and Managing Member of Santa Barbara Financial Services, LLC since 2008. Prior to founding Santa Barbara Financial Services, he served as the Chief Financial Officer and Treasurer of Mentor Corporation, a medical equipment company, from 2004 to 2007. Prior to that, Mr. McFarland fulfilled various finance and accounting roles at Mentor from 1985 to 2004. He worked as a Certified Public Accountant and Audit Supervisor with Touche Ross & Co., an accounting firm, from 1981 to 1985 and served in the North Dakota Army National Guard from 1978 to 1984. He currently serves on the Board of Directors and as the Chief Financial Officer of Cure Medical, LLC, a privately held manufacturer of disposable urology products, on the Board of Directors of the MIT Enterprise Forum of the Central Coast and chairs the parish finance council for St. Mark’s University Parish, Isla Vista, CA. Previously, Mr. McFarland served on the Board of Directors of Patient Safety Technologies, Inc., an acquired publicly-traded medical device company, as the Financial Expert on the Audit Committee and as a Member of the Compensation, Nominating and Governance Committee. Mr. McFarland has a Bachelor of Arts degree in Accounting from the University of North Dakota and an M.B.A. from the University of California, Los Angeles. He completed an ISS Director Certification Program in October 2008 at the University of California, Los Angeles’ Anderson School. The Board believes that he is qualified to serve as a director of Inogen because of his leadership experience and his extensive experience in finance and accounting.
As the Independent Director of Inogen Inc, the total compensation of Loren McFarland at Inogen Inc is 235,022$. There are 11 executives at Inogen Inc getting paid more, with Scott Wilkinson having the highest compensation of 2,520,530$.
Loren McFarland is 61, he's been the Independent Director of Inogen Inc since 2013. There are 1 older and 15 younger executives at Inogen Inc. The oldest executive at Inogen Inc is Benjamin Anderson-Ray, 65, who is the Independent Director.
Loren's mailing address filed with the SEC is C/O INOGEN, INC., 301 COROMAR DRIVE, GOLETA, CA, 93117.
Over the last 11 years, insiders at Inogen Inc have traded over 242,179,025$ worth of Inogen Inc stock and bought 9,125 units worth 253,950$ . The most active insiders traders include Holdings A/S Novo、Timothy Petersen、Raymond Huggenberger. On average, Inogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of 321,391$. The most recent stock trade was executed by Jason Somer on 1 June 2024, trading 577 units of INGN stock currently worth 6,670$.
inogen’s mission to improve the quality of life of supplemental oxygen users began in 2001 when mae, a beloved grandmother, was prescribed oxygen therapy. learn more about mae’s story here: http://www.inogen.com/about-inogen/meet-mae/. inogen was founded based on our conviction that oxygen therapy technology was not keeping pace with the desired lifestyles of patients who depended on it to live longer, more fulfilling lives. we estimate that more than 2.5 million patients in the united states and more than 4.5 million patients worldwide use oxygen therapy. our compact, lightweight and travel-approved portable oxygen concentrators are designed to free patients from heavy tanks, managing tank refills or being tethered to stationary systems. we believe our products allow oxygen therapy patients to reclaim their freedom and independence so that life can be lived in moments, not in minutes left in an oxygen tank. with each step we take to improve our products and service, our customers take
Inogen Inc executives and other stock owners filed with the SEC include: